Unichem Laboratories Q1 FY17 results (Apr–Jun 2016) and concall

Unichem Labs reported a solid Q1 FY17 with a 9.5% increase in total income from operations and 12% growth in its domestic formulations business. Despite a lower PAT due to higher deferred tax and a Rs. 7 Crores provision for its Brazilian subsidiary, management expressed confidence in future growth driven by new product launches, expanded capacities, and strategic initiatives like moving Unienzyme to the OTC market. The company also outlined significant capex plans for FY17-18, primarily for its Kolhapur API facility.